MolDX: Melanoma Risk Stratification Molecular Testing (L37748) - R8 - Effective June 26, 2025

Date Posted: October 16, 2025

This MolDX Local Coverage Determination (LCD) has been revised under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: June 26, 2025

Summary of Changes:

Under Summary of Evidence Paragraph 5 updated sentence "Importantly, the 5-year melanoma specific survival (MSS) rate for T1/T2 low-risk group remains favorable; with 99% MSS, comparable to that observed in T1a tumors and for which current guidelines do not recommend SLNB. 2,27" Updated Bibliography Reference #19.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCD or access it via the CMS Medicare Coverage Database (MCD).

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )